Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.40 |
| ▸ | CDK9 | P50750 | 7/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524004 | 1.00 | CCNT1 (0.40) | CCNT1CDK9RORCJAK1P2RX7 | |
| SCHEMBL18866820 | 0.85 | CCNT1 (0.40) | CCNT1CDK9JAK1LRRK2 | |
| SCHEMBL2521073 | 0.85 | CCNT1 (0.50) | CCNT1CDK9RORC | |
| SCHEMBL2521074 | 0.85 | CCNT1 (0.50) | CCNT1CDK9RORC | |
| SCHEMBL2510863 | 0.78 | KDM4E (0.51) | CCNT1CDK9RORCALDH1A1MAPT | |
| SCHEMBL2510864 | 0.78 | KDM4E (0.51) | CCNT1CDK9RORCALDH1A1MAPT | |
| SCHEMBL2523997 | 0.78 | CCNT1 (0.37) | CCNT1CDK9JAK1L3MBTL1GAA | |
| SCHEMBL2523991 | 0.78 | CCNT1 (0.37) | CCNT1CDK9JAK1L3MBTL1GAA | |
| SCHEMBL2519112 | 0.76 | GRM1 (0.41) | CCNT1CDK9RORC | |
| SCHEMBL2519111 | 0.76 | GRM1 (0.41) | CCNT1CDK9RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558467-B1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-8461151-B2 | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2558467-A1 | ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011128265-A1 | ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | OXTR, AVPR1B, AVPR1A | CCNT1 1550/4885CDK9 3334/4885RORC 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.